Search bioRxiv⌕ Search

Biology subjects

Emanuelli Castaner, A.

Publications and source records attributed to Emanuelli Castaner, A..

4 recordsLinked to original sources

Structural, biophysical, and virological mechanistic characterization of HIV-1 capsid-targeting antivirals

Due to its significant role in virus replication, the HIV capsid is an attractive antiviral target. This is validated by the recent clinical approval of lenacapavir for both treatment and pre-exposure prophylaxis (PrEP). PF74 is a well-characterized capsid-targeting antiviral that was discontinued in further study due to potency and metabolic issues. We hypothesized that making chemical modifications at certain sites of PF74 could result in capsid-targeting antivirals with improved potency and bioavailability. Our cumulative studies show that making changes at the R1 and R3 positions of PF74 results in compounds with increased antiviral potency, increased stability of wild-type HIV capsid hexamers and virions, tighter binding to wild-type HIV capsid hexamer compared to PF74, and different interactions at the "FG" binding site of capsid compared to PF74. These data provide insights into the design of future capsid-targeting antivirals relevant for clinical use.

biochemistry↗

Translocation of HIV capsid core through the Nuclear Pore Complex by affinity gradient

The HIV capsid core encapsulates the viral genome for subsequent integration into host cellular DNA. Prior to nuclear entry, the core must translocate through the Nuclear Pore Complex (NPC). This transit involves interactions between the capsid core and phenylalanine-glycine (FG) repeats found in nucleoporins within the NPC. Despite this critical role in the viral replication cycle, the molecular mechanism of capsid core translocation remains unclear. FG repeats consist of three classes of canonical motifs: FG, GLFG, and FxFG motifs. These are segregated within the NPC to define distinct zones of the gating machinery. FG- and FxFG-type motifs are enriched in the cytoplasmic and nuclear ("nuclear basket") peripheries of the NPC while GLFG motifs are enriched in regions adjacent to the core of the NPC. To investigate the capsid core translocation, we use biochemical, biophysical, and structural approaches to study FG-capsid interactions in a quantitative manner. We show that the capsid (CA) interacts with a range of diverse FG repeats with varying affinities. GLFG motifs of core NUP98 exhibit increased affinity to CA proteins compared to other conventional FG/FxFG. However, the non-canonical FxFG motif of NUP153 at the "nuclear basket" significantly increases binding affinity to CA compared to canonical FxFG, therefore called FG super-motif. In addition, C-terminal motif of NUP153 consists of a stretch of basic residues, which enhances the affinity of this non-canonical FG super-motif to capsid core at the NPC nuclear periphery. We identified other binding enhancers of the NPC core FG-NUPs, NUP58 and POM121. The relationship between the binding strength of FG/FxFG binding enhancers of NUP58, POM121, NUP153 and their position within the NPC also shows capsid core binding affinity increases with increasing proximity to the "nuclear basket." Based on our data, the difference in binding affinities between the canonical FxFG motif and the enhancer-coupled FG super-motif of NUP153 to capsid cores at the "nuclear basket" is approximately 1,000-fold. Therefore, the diverse FG motifs and binding enhancers, which are naturally distributed within the NPC into distinct zones, create an avidity gradient--with changes in both concentration and binding affinity--along the cytoplasmic-nuclear axis. We suggest that HIV capsid translocation into the nucleus is potentiated by this gradient in a unidirectional manner (outside- to-inside) within the NPC.

microbiology↗

Characterization of antiviral compounds using Bio-Layer Interferometry

Small molecule-protein interactions underpin many biological functions and play an integral role in the treatment and prevention of several human diseases. These interactions can be key to understanding the mechanism of action of these compounds. Previous methods of determining protein-protein or protein-antibody interactions have been well established; however, the use of BLI in antiviral discovery is a promising and relatively new avenue. The high-throughput nature of this method in tandem with its pM sensitivity allows for quick and seamless identification of hit compounds. Here we discuss ways to overcome common pitfalls that can occur while using BLI such as nonspecific binding (NSB) and ligand drift while offering possible solutions. Characterizing small molecule-protein interactions is not trivial and optimizing the experimental conditions is imperative. To address this gap in knowledge, we present optimized BLI protocols for the study of three cases of protein-small molecule interactions: PF74 or Lenacapavir (LEN) with HIV-1 capsid protein (CA), and Nirmatrelvir (NIR) with SARS-CoV-2 Mpro. LEN and NIR are of particular interest because they are clinically relevant, and PF74, a well-studied control, was the first compound reported to target the LEN binding site. We demonstrate that BLI can be a powerful and effective tool in calculating the binding affinities between a protein and small molecule. These newly designed methods enabled calculation of KD values, the affinity between ligand and analyte, ranging from the micro to the sub-nanomolar range for CA binding events and confirmed the covalent interaction between NIR and Mpro. These protocols will facilitate efficient testing of new antivirals or derivatives in a high- throughput format. SummaryBio-Layer Interferometry (BLI) is a multifunctional technology that is used to determine valuable information on real-time kinetics including association and dissociation. Optimizing experimental conditions to acquire data about protein-ligand interactions can be challenging. We provide three example methods of collecting binding data that characterize how viral proteins interact with antivirals.

biochemistry↗

Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies

The antiviral component of Paxlovid, nirmatrelvir (NIR), forms a covalent bond with Cys145 of SARS-CoV-2 nsp5. To explore NIR resistance we designed mutations to impair binding of NIR over substrate. Using 12 Omicron (BA.1) and WA.1 SARS-CoV-2 replicons, cell-based complementation and enzymatic assays, we showed that in both strains, E166V imparted high NIR resistance ([~]55-fold), with major decrease in WA1 replicon fitness ([~]20-fold), but not BA.1 ([~]2-fold). WA1 replicon fitness was restored by L50F. These differences may contribute to a potentially lower barrier to resistance in Omicron than WA1. E166V is rare in untreated patients, albeit more prevalent in paxlovid-treated EPIC-HR clinical trial patients. Importantly, NIR-resistant replicons with E166V or E166V/L50F remained susceptible to a) the flexible GC376, and b) PF-00835231, which forms additional interactions. Molecular dynamics simulations show steric clashes between the rigid and bulky NIR t-butyl and {beta}-branched V166 distancing the NIR warhead from its Cys145 target. In contrast, GC376, through "wiggling and jiggling" accommodates V166 and still covalently binds Cys145. PF-00835231 uses its strategically positioned methoxy-indole to form a {beta}-sheet and overcome E166V. Drug design based on strategic flexibility and main chain-targeting may help develop second-generation nsp5-targeting antivirals efficient against NIR-resistant viruses.

microbiology↗